US.JNJ · Johnson & Johnson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 2,
      "details": {
        "atrPct": 1.9858456172012158,
        "turnoverUsdM": 1290.3637863961699,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.JNJ",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 255.7714,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2.5,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 4,
      "take_profit_price": 279.6675,
      "target_multiplier": 1.6,
      "technical_strength": 1.45,
      "take_profit_percent": 5
    },
    "positionPoints": 2,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2589095437959654,
    "stopLossPercent": 3.9716912344024315,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 51,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 48,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 269.269,
    "ma50": 262.4766,
    "close": 266.35,
    "prevClose": 267.08,
    "avgVolume20": 6258166,
    "volumeRatio": 0.77,
    "changePercent": -0.27
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.03219352611436821,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.7754613119057528,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.1895540753392857,
      "volat_points": 0,
      "day_range_pct": 0.02083720590061168,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 51,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 86,
        "contribution": 4.3
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 6.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 42.67,
        "contribution": 6.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 78,
        "contribution": 7.8
      },
      {
        "raw": 17.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59,
        "contribution": 17.7
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 48,
    "details": [
      "基本面分析總分: 4.3/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 6.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.8/10分",
      "技術信號分析總分: 17.7/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.3,
      "資金流": 6.8,
      "市場環境": 6.4,
      "情緒分析": 3,
      "技術信號": 17.7,
      "風險管理": 7.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 1290.3637863961699,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.JNJ",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.9858456172012158,
          "atrPoints": 4,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142064746,
                "url": "https://finnhub.io/api/news?id=1abe8e7dab24ae7989315403c7be9a89f24836f0d543d8d14ac5a49793d3b96e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.",
                "category": "company",
                "datetime": 1789063054,
                "headline": "JNJ Stock: Is the Rally Running Out of Steam?"
              },
              {
                "id": 142028628,
                "url": "https://finnhub.io/api/news?id=1197e6dcb84032bc3178511ebc59fde338fc46553b3e766a32b3e59929344ec1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]",
                "category": "company",
                "datetime": 1788981160,
                "headline": "Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks"
              },
              {
                "id": 142027249,
                "url": "https://finnhub.io/api/news?id=8fed0c65d5a94df09a2a26499cf9c6168ec3911a7c71d4477358268d1b8aea34",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1788962224,
                "headline": "Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141955082,
                "url": "https://finnhub.io/api/news?id=ba3edbedd7a34d8245d39dd84b936c126d015e3411c20efa069bf46bba2df73a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to its last close.",
                "category": "company",
                "datetime": 1788903908,
                "headline": "Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 141949784,
                "url": "https://finnhub.io/api/news?id=1459d852c5cf1a923b01ee1ca27949ec1696499029b7a48c7884b7367c37778b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer called the JNJ dip a buying opportunity live on air, but the data behind his reasoning had already been published hours earlier, and the stock's recent performance tells a very different story than a typical defensive play.",
                "category": "company",
                "datetime": 1788880212,
                "headline": "Cramer Says It’s Time To Buy The Dip on JNJ"
              },
              {
                "id": 141444058,
                "url": "https://finnhub.io/api/news?id=905919b186b2cb70f624aa1750860bd8a239d54c5d4daa0db9581cc8254fae21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.",
                "category": "company",
                "datetime": 1788541047,
                "headline": "Was JNJ Stock Rally Actually Its Own?"
              },
              {
                "id": 141407972,
                "url": "https://finnhub.io/api/news?id=26207fd779a0709c01bc9cc40acf91834bbe5574829ddb55f213710b0d10fed5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is back in the spotlight after a Louisiana jury found the company liable in a talc related mesothelioma case, adding a fresh layer to its ongoing litigation risk. Against this backdrop, Johnson & Johnson’s recent 7 day share price return of 4.76% and 30 day share price return of 9.22% indicate that momentum has been building ahead of the Louisiana verdict and the latest FDA approval, while the 1 year total shareholder return of 59.27% and 5 year total shareholder...",
                "category": "company",
                "datetime": 1788496619,
                "headline": "Is Johnson & Johnson (JNJ) Cheap After The Louisiana Talc Verdict?"
              },
              {
                "id": 141373023,
                "url": "https://finnhub.io/api/news?id=e3266eba8d7c7f32c4ee173ae3bfd8a04ad772c1b53d5cd7267bcbf9be985087",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) was found liable by a Louisiana jury in a high-profile talc-related mesothelioma case, adding a fresh verdict to its ongoing talc litigation. The jury decision centers on alleged asbestos exposure from Johnson & Johnson talc products and raises questions about potential future legal costs for the company. This verdict contributes to the broader legal overhang that investors weigh alongside Johnson & Johnson's core healthcare operations and balance sheet...",
                "category": "company",
                "datetime": 1788318651,
                "headline": "Does Johnson & Johnson (JNJ) Talc Verdict Add To Its Legal Risk?"
              }
            ],
            "raw_source": [
              {
                "id": 142064745,
                "url": "https://finnhub.io/api/news?id=ec7e31288ec30d3ed445c243aaa5470eb1ec4dfe7aa9137eda86ec50309ce44d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.",
                "category": "company",
                "datetime": 1789067434,
                "headline": "Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?"
              },
              {
                "id": 142064394,
                "url": "https://finnhub.io/api/news?id=adf9fabb65fa1bdc0746c8cf7941b566bd25d62715d8b6fa00e9d6a2953470bc",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1789067407,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 142064755,
                "url": "https://finnhub.io/api/news?id=41a9a1300a4a9ac8c6721be13f0b0874e47f4e959ff2b39ec0929c17d38a79fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Cooper Cos. stock has fallen about 25% since Barron’s recommended it, but a low valuation, aggressive share buybacks, and takeover potential bolster the bull case.",
                "category": "company",
                "datetime": 1789064640,
                "headline": "Barron’s Got Cooper Wrong but the Contact-Lens Stock Now Looks Cheap"
              },
              {
                "id": 142064746,
                "url": "https://finnhub.io/api/news?id=1abe8e7dab24ae7989315403c7be9a89f24836f0d543d8d14ac5a49793d3b96e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.",
                "category": "company",
                "datetime": 1789063054,
                "headline": "JNJ Stock: Is the Rally Running Out of Steam?"
              },
              {
                "id": 142063248,
                "url": "https://finnhub.io/api/news?id=ad29399e84b41bc1339b127b911b623aa95a44e467ef9e53072ffcdee0c255de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $500 a month from dividends sounds straightforward until you see how wildly the required capital swings depending on which stocks you pick and which trade-offs you are willing to accept.",
                "category": "company",
                "datetime": 1789062427,
                "headline": "The Portfolio You Need to Generate $500 a Month in Dividend Income"
              },
              {
                "id": 142063291,
                "url": "https://finnhub.io/api/news?id=45a4c767641875677341490c5c57df95988778e7db0af9183d8a84bc58b8398b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.",
                "category": "company",
                "datetime": 1789059954,
                "headline": "Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?"
              },
              {
                "id": 142063284,
                "url": "https://finnhub.io/api/news?id=be50a481ebcc5df0107d02787d9814e4fad26b357f7714cbff406902f2e7efa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.",
                "category": "company",
                "datetime": 1789055640,
                "headline": "AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next"
              },
              {
                "id": 142061785,
                "url": "https://finnhub.io/api/news?id=319f28aeaea63b63ec1d3933aeb670aebb9c5465de023eaec04e187f46e57e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.",
                "category": "company",
                "datetime": 1789052702,
                "headline": "Why Has AbbVie Gone Quiet About Humira?"
              },
              {
                "id": 142060678,
                "url": "https://finnhub.io/api/news?id=46cbf9716b071176637f70de8b37c680fc881c336af2efec6ab4ba00c707cde1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Six-week agent training program recognized for sales performance and innovation after attracting more than 21,000 registrations. BELLINGHAM, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- eXp Realty®, the most agent-centric™ real estate brokerage on the planet and the core subsidiary of AGNT, Inc. (Nasdaq: AGNT), today announced that eXp University’s FastCAP program earned two Gold awards in the 2026 Brandon Hall Group Excellence Awards, an international competition featuring organizations including",
                "category": "company",
                "datetime": 1789045200,
                "headline": "eXp University’s FastCAP Wins Two Gold Awards in Global Field Beating Out 3M, IBM, and Pepsi"
              },
              {
                "id": 142060078,
                "url": "https://finnhub.io/api/news?id=5c74f69b93b992bfe256b28a875edb9f706d15240b680468af9dffe6a096a3f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LIMERICK, Ireland, September 10, 2026--Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies.",
                "category": "company",
                "datetime": 1789040700,
                "headline": "Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses"
              },
              {
                "id": 142060079,
                "url": "https://finnhub.io/api/news?id=cad72b439ce22a1a75e500ebe10c80d05194f813da450bf2f102c06c57d1998e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Contact lens maker  Cooper Companies  just sprung a surprise that no one saw coming.  The market had been looking ahead to the potential sale of its women’s health and fertility business CooperSurgical.  The stock tumbled more than 15% ahead of the open Thursday, by far the biggest faller in the  in premarket trading.",
                "category": "company",
                "datetime": 1789036200,
                "headline": "2 Reasons Cooper Companies Stock Is By Far the Worst in the S&P 500 Today"
              },
              {
                "id": 142066034,
                "url": "https://finnhub.io/api/news?id=a99b219a1d6dc3956168638bf6407c80ad5d06b5cab7893ea4565db07aeec79f",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $290 to $320.",
                "category": "company",
                "datetime": 1789033510,
                "headline": "HSBC Maintains Buy on Johnson & Johnson, Raises Price Target to $320"
              },
              {
                "id": 142053754,
                "url": "https://finnhub.io/api/news?id=111ee4a5d6154b8bd4fc22fa452b8248654e3f07d3b28b40bdf534f8961451ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "2026 China International Fair for Trade in Services BEIJING, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The 2026 China International Fair for Trade in Services (CIFTIS) opened Wednesday in Beijing, as China steps up efforts to expand opening-up in services trade at the outset of the 15th Five-Year Plan period (2026-2030). Running through Sept. 13 at Shougang Park, a former industrial site and venue for the Beijing 2022 Winter Olympics, the fair has drawn participants from 90 countries, regions and inter",
                "category": "company",
                "datetime": 1789032780,
                "headline": "China services trade fair showcases innovation, promotes openness"
              },
              {
                "id": 142066035,
                "url": "https://finnhub.io/api/news?id=01568668b3eab3cb40e33963c7910a2fedc1051a2641227f9766b79689841a2b",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "New 2-week reusable contact lens brings advanced ACUVUE OASYS MAX technologies to deliver superior comfort and visual clarity to patients, even at day 14Expands the ACUVUE OASYS MAX portfolio with an advanced option for",
                "category": "company",
                "datetime": 1789026510,
                "headline": "Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week, New Reusable Contact Lens Featuring Proprietary MAX Technologies To Deliver Lasting Comfort And Clear Vision, Even At Day 14"
              },
              {
                "id": 142037821,
                "url": "https://finnhub.io/api/news?id=111db1e73b95e44821420ce4a7307dd477cbd22ec124737b00e8ef9d99e156e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.",
                "category": "company",
                "datetime": 1789007538,
                "headline": "Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes"
              },
              {
                "id": 142031044,
                "url": "https://finnhub.io/api/news?id=e0888874bcc9d0ab00107c6f1ba8ec17e6b2c19967d9204a18d17b1fadd74b4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision gives the company another route into a market where more than 8.4 million people are affected by psoriasis, according to J&J. Icotyde could appeal to patients who prefer a pill over an injectable treatment, potentially […]",
                "category": "company",
                "datetime": 1788995136,
                "headline": "Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?"
              },
              {
                "id": 142031045,
                "url": "https://finnhub.io/api/news?id=fcefd8ee7d1d93556d32db986fa487544a63aeedecb0b8afacdc57edc4e57503",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wiping out your mortgage with one 401(k) withdrawal feels like a power move, but the tax bracket you land in that year tells a very different story about who actually wins.",
                "category": "company",
                "datetime": 1788990929,
                "headline": "Paying Off the House With Your 401(k) Feels Smart but Can Cost Six Figures. These 3 ETFs Are Why You Keep the Money Invested"
              },
              {
                "id": 142029776,
                "url": "https://finnhub.io/api/news?id=d0731908caf2bd1afebdf178ac483ad1e6acebd96431ddace79e6a6f8dcaac48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.",
                "category": "company",
                "datetime": 1788986503,
                "headline": "What Eli Lilly Was Telling You While It Rationed Its Own Launches"
              },
              {
                "id": 142029783,
                "url": "https://finnhub.io/api/news?id=1aa1e22c6ac3142237a0016f4299f278aafa537090db39915324d58d984718f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.",
                "category": "company",
                "datetime": 1788985334,
                "headline": "How Much Can ISRG Stock Still Move Against You?"
              },
              {
                "id": 142028628,
                "url": "https://finnhub.io/api/news?id=1197e6dcb84032bc3178511ebc59fde338fc46553b3e766a32b3e59929344ec1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]",
                "category": "company",
                "datetime": 1788981160,
                "headline": "Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks"
              },
              {
                "id": 142028236,
                "url": "https://finnhub.io/api/news?id=3f9396fd378945ab289f1fef5df0f06f15cd8f5cea04f043344d77ae53f1a0a4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1788981004,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 142028634,
                "url": "https://finnhub.io/api/news?id=80e7de8999e6a41acd61752ba4a09ba315b534d097c582121d26f62ef8d54a24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak.  Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point.  Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.",
                "category": "company",
                "datetime": 1788977210,
                "headline": "BSX Stock: Is It Time To Buy Or Sell Puts?"
              },
              {
                "id": 142027366,
                "url": "https://finnhub.io/api/news?id=92731cf07c1cfb3c4fcaf55a59c8ff8267e4af6171c5ef38957d6790d53461d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Citi just slapped a Buy rating on UiPath with a target nearly 70% above the current price, yet shares keep falling. Here is what the bull and bear camps are fighting over ahead of a high-stakes investor day that could flip the narrative.",
                "category": "company",
                "datetime": 1788975908,
                "headline": "UiPath Slips 3% Despite Citi Buy Initiation and $23 Target, Pegasystems and C3.ai Lag"
              },
              {
                "id": 142027364,
                "url": "https://finnhub.io/api/news?id=2b0cc9babe12ed31772ecc863bfceffc7080729d23e8f8b75d240652cd106403",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-m",
                "category": "company",
                "datetime": 1788973345,
                "headline": "Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage"
              },
              {
                "id": 142029781,
                "url": "https://finnhub.io/api/news?id=2060aae0898ceada16407d21d4c2d5d4869b5a119cdecb29f2aacc114256adef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.",
                "category": "company",
                "datetime": 1788968760,
                "headline": "Tyra disappoints investors with bladder cancer data"
              },
              {
                "id": 142027365,
                "url": "https://finnhub.io/api/news?id=7b2bb0cc2eb7e05d14cc79cc2ccb569167da6bd399edfbf337cb8d5ee734bb54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.",
                "category": "company",
                "datetime": 1788965040,
                "headline": "Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress"
              },
              {
                "id": 142025918,
                "url": "https://finnhub.io/api/news?id=c3cf022ea6e9c4982ab7f98aee1428d9828607a84c943092ff82c901dcae913f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A seven-holding portfolio promising $12,500 a month sounds straightforward until you examine whose money is actually funding some of those distributions, and why the highest-yielding positions have the weakest claim to keeping their promises.",
                "category": "company",
                "datetime": 1788962922,
                "headline": "How Large Does Your Portfolio Need to Be to Generate $12,500 a Month?"
              },
              {
                "id": 142027249,
                "url": "https://finnhub.io/api/news?id=8fed0c65d5a94df09a2a26499cf9c6168ec3911a7c71d4477358268d1b8aea34",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1788962224,
                "headline": "Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142024726,
                "url": "https://finnhub.io/api/news?id=c0d76a8928e2fd50eb24afaead652811d0bc0a50082e531baea6c1e64d4b6a32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.",
                "category": "company",
                "datetime": 1788955235,
                "headline": "IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?"
              },
              {
                "id": 142025638,
                "url": "https://finnhub.io/api/news?id=de527c4017ba098f6eddbb8037d3d85d0ebe5f38f4beb47c5dcb23bcd820f5b4",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.reuters.com/business/healthcare-pharmaceuticals/tylenol-use-pregnancy-may-be-linked-with-uterus-ovary-changes-daughters-2026-09-09/",
                "category": "company",
                "datetime": 1788947467,
                "headline": "Reported September 8, 2026: 'Tylenol Use In Pregnancy May Be Linked With Uterus, Ovary Changes In Daughters' - Reuters News"
              },
              {
                "id": 141955082,
                "url": "https://finnhub.io/api/news?id=ba3edbedd7a34d8245d39dd84b936c126d015e3411c20efa069bf46bba2df73a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to its last close.",
                "category": "company",
                "datetime": 1788903908,
                "headline": "Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 141955083,
                "url": "https://finnhub.io/api/news?id=8956c39c748a06e833b1ef01d045e85a4fcd28883cfef04cd62a57ff190baf49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEWARK, CA / ACCESS Newswire / September 8, 2026 / , Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock.",
                "category": "company",
                "datetime": 1788897900,
                "headline": "Protagonist Therapeutics Announces $300 Million Share Repurchase Program"
              },
              {
                "id": 141953455,
                "url": "https://finnhub.io/api/news?id=c0bbe00c3de9e1f537c499d1785bfb81b11a11392b437598f038f326339af575",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1788894604,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 141952574,
                "url": "https://finnhub.io/api/news?id=231c436dd90d1bd37d6f9fbfe5069ae8c4282e95b04cd5d4be6c6342e9a2b874",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Between winding down some legacy operations, executing major cost-cutting initiatives and navigating skyrocketing freight and fuel costs, J&J Snack Foods is going through something of a transition year.",
                "category": "company",
                "datetime": 1788889187,
                "headline": "Exclusive: J&J Snack Foods CEO sees a leaner business set up to return to growth"
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 141952073,
                "url": "https://finnhub.io/api/news?id=5ed9c9ef40acd5c017324f75f1cda8dd92993808c451df6bde6b702e36240df6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1788885606,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 141949784,
                "url": "https://finnhub.io/api/news?id=1459d852c5cf1a923b01ee1ca27949ec1696499029b7a48c7884b7367c37778b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer called the JNJ dip a buying opportunity live on air, but the data behind his reasoning had already been published hours earlier, and the stock's recent performance tells a very different story than a typical defensive play.",
                "category": "company",
                "datetime": 1788880212,
                "headline": "Cramer Says It’s Time To Buy The Dip on JNJ"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 142024727,
                "url": "https://finnhub.io/api/news?id=ff4651ba2f985c8b71bd89c2ed42f9ed86787c5cdae1b0c6783c0a9da29ce030",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Ahead of CPI data and the Fed's rate decision, defensive stocks McDonald's, Johnson & Johnson, Walmart, Berkshire Hathaway, and NextEra Energy offer stability and dividends amid market uncertainty.",
                "category": "company",
                "datetime": 1788875100,
                "headline": "5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test"
              },
              {
                "id": 141950011,
                "url": "https://finnhub.io/api/news?id=45f6beae1cb87cb5934a9bb791896821d4927a4037874d9e0ab47362c5b27dfd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage profiles could shift that math entirely in a retiree's favor.",
                "category": "company",
                "datetime": 1788871206,
                "headline": "Want Dividends to Pay Your Medicare Premiums? Here’s How Much You Need"
              },
              {
                "id": 141950012,
                "url": "https://finnhub.io/api/news?id=0950f72953663fb21dcb97f971491bd7ad654036c2ffe3f992dd8c1bf4e769ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).",
                "category": "company",
                "datetime": 1788868800,
                "headline": "Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026"
              },
              {
                "id": 141950016,
                "url": "https://finnhub.io/api/news?id=f663b4833cd38e00cacc7c46a1429b8951d9f7cbfff93a948b14098a83e0d5b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JEPI's monthly paycheck looks irresistible until you see exactly what the fund surrenders to produce it. Three Dividend Kings quietly sidestep that tradeoff, and the difference compounds in ways most income investors never stop to calculate.",
                "category": "company",
                "datetime": 1788868213,
                "headline": "JEPI Is an Income Machine—But These 3 Dividend Stocks Don’t Cap Your Upside"
              },
              {
                "id": 141951906,
                "url": "https://finnhub.io/api/news?id=8516a4e5e27068b7c69780eccea33f98d398d6703fa4e598ec89e1e4baf85c7b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Eli-Lilly-And-Company-Logo-On-Dark-Backg.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.",
                "category": "company",
                "datetime": 1788866855,
                "headline": "Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back"
              },
              {
                "id": 141868205,
                "url": "https://finnhub.io/api/news?id=fcfa5e246cc835c64f0d7b5ddb14a2a1a880c36572c3dc06c22aeb5a62e5d566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by ri",
                "category": "company",
                "datetime": 1788856260,
                "headline": "Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio"
              },
              {
                "id": 141953827,
                "url": "https://finnhub.io/api/news?id=a84b325901e324bc3fda63a6fbedd8cf0e873290fc36edb310413cd977887ba9",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting",
                "category": "company",
                "datetime": 1788854594,
                "headline": "Johnson & Johnson To Present Data Across Its Neuropsychiatry Portfolio at 2026 Psych Congress Annual Meeting"
              },
              {
                "id": 141940491,
                "url": "https://finnhub.io/api/news?id=4f321fdcb5abe73f9b90bad7d6eb4396c0b873d51bdae1026cb95ca11a1f74f3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217834289/image_2217834289.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Compare dividend growth vs. high-yield investing with PTY vs. JNJ and VFC vs. MPW tests. Click here for a detailed analysis.",
                "category": "company",
                "datetime": 1788852931,
                "headline": "Dividend Growth Vs. High Yield - The Winner Is Clear"
              },
              {
                "id": 141913510,
                "url": "https://finnhub.io/api/news?id=93030636154aeb4442631985be95aeeb84233bfcad77a6092698cf29fcc0784c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238217382/image_2238217382.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.",
                "category": "company",
                "datetime": 1788848276,
                "headline": "Health Care's Next Act: Tailwinds Emerging Across R&D Cycle"
              },
              {
                "id": 141763843,
                "url": "https://finnhub.io/api/news?id=8e3a96e4ac86779de5d67800a375b6f80af9249e291b76853665ea38ecde2666",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.",
                "category": "company",
                "datetime": 1788793380,
                "headline": "Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?"
              },
              {
                "id": 141763608,
                "url": "https://finnhub.io/api/news?id=9db646230248d10b57716e13d297968726d5f57d49dd2c5e1c386b675ca2c022",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.",
                "category": "company",
                "datetime": 1788792021,
                "headline": "Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?"
              },
              {
                "id": 141761725,
                "url": "https://finnhub.io/api/news?id=15b7097ab093e3328d54587147986286cdb1a12a46e47e149417d4775524e2f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 481 Targets, 350 Deals, and 1,100+ Funding Rounds as Amgen, Roche, and J&J Lead a Field That Saw 278 New Drugs in 2024/25 AloneDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence\" has been added to ResearchAndMarkets.com's offering. Bi/Multispecific Drugs in Oncology Analytical Tool Delivers Near-Real-Time Intelligence for Oncology Drug",
                "category": "company",
                "datetime": 1788775200,
                "headline": "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline"
              },
              {
                "id": 141761420,
                "url": "https://finnhub.io/api/news?id=4f2802aa4ef24aef7667975d5a4b559ef64630292829d06fe129c3b40461cdab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Surgical Robots Market by Offering of Surgical Robot Developers, Deployment Model, Type of Surgical Procedure Supported, Application Area, End Users and Key Geographical Regions - Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.",
                "category": "company",
                "datetime": 1788769260,
                "headline": "Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery"
              },
              {
                "id": 141591495,
                "url": "https://finnhub.io/api/news?id=b8ebd6fefc1601822ef27440145c46446ce08b6a0c2b7926299df69372ac11e8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2292236378/image_2292236378.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Tyra Biosciences (TYRA) downgraded to Hold ahead of phase 2 SURF302 data; review FGFR3-targeting SNAP platform, cash runway, and key catalysts—read now.",
                "category": "company",
                "datetime": 1788693258,
                "headline": "Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts"
              },
              {
                "id": 141586678,
                "url": "https://finnhub.io/api/news?id=4de66b41d29d7cc8504256e7940888d6e859ba6698d1168700339f11da8722be",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2287002303/image_2287002303.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "August CPI and key earnings are in focus: Oracle, Adobe, Macy’s, and more.",
                "category": "company",
                "datetime": 1788676640,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141525606,
                "url": "https://finnhub.io/api/news?id=63ea1dba5b78b36a241409827bb3e0a2c3aa844307e0c561b62eb0ee513211ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Treasury yields near a one-year high are punishing most dividend stocks, but a handful of Dividend Kings kept signing bigger checks every single quarter without missing a beat. The question is whether their balance sheets can keep that streak alive.",
                "category": "company",
                "datetime": 1788619054,
                "headline": "3 Dividend Kings Built to Keep Raising Your Income When Rates Rise"
              },
              {
                "id": 141455029,
                "url": "https://finnhub.io/api/news?id=9980113490b89d23a66c8ffb6cd96ecfaacbd42b6a644618293f4755fb4708bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.",
                "category": "company",
                "datetime": 1788546339,
                "headline": "How Much Upside Can BSX Stock's Growth Deliver?"
              },
              {
                "id": 141444058,
                "url": "https://finnhub.io/api/news?id=905919b186b2cb70f624aa1750860bd8a239d54c5d4daa0db9581cc8254fae21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.",
                "category": "company",
                "datetime": 1788541047,
                "headline": "Was JNJ Stock Rally Actually Its Own?"
              },
              {
                "id": 141431563,
                "url": "https://finnhub.io/api/news?id=98809543db63402ec6095cbd5d0be1907535a39dce427a40177fbe4b2a1e11a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.",
                "category": "company",
                "datetime": 1788530660,
                "headline": "Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect."
              },
              {
                "id": 141446631,
                "url": "https://finnhub.io/api/news?id=acc97bf164cbb510d5f95d4dd90bb12e4789e33a92896040efbc52ce5956ac8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.",
                "category": "company",
                "datetime": 1788523200,
                "headline": "Trailing rivals, AbbVie scores win with dual-acting myeloma drug"
              },
              {
                "id": 141449914,
                "url": "https://finnhub.io/api/news?id=c131e353d1a0994a03b0822c19aeb42be3b39887f8759085eae491d6d8cd96fd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Highlighted on September 4, it was unveiled in an SEC filing that Schmid, EVP at Johnson & Johnson (NYSE:JNJ), executed a significant transaction involving the exercise of company stock options.\nWhat Happened:",
                "category": "company",
                "datetime": 1788519679,
                "headline": "Timothy Schmid Exercises Options, Realizes $4.39M"
              },
              {
                "id": 141407972,
                "url": "https://finnhub.io/api/news?id=26207fd779a0709c01bc9cc40acf91834bbe5574829ddb55f213710b0d10fed5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is back in the spotlight after a Louisiana jury found the company liable in a talc related mesothelioma case, adding a fresh layer to its ongoing litigation risk. Against this backdrop, Johnson & Johnson’s recent 7 day share price return of 4.76% and 30 day share price return of 9.22% indicate that momentum has been building ahead of the Louisiana verdict and the latest FDA approval, while the 1 year total shareholder return of 59.27% and 5 year total shareholder...",
                "category": "company",
                "datetime": 1788496619,
                "headline": "Is Johnson & Johnson (JNJ) Cheap After The Louisiana Talc Verdict?"
              },
              {
                "id": 141404317,
                "url": "https://finnhub.io/api/news?id=12b75245389688b8b71b8fe4f31a39d86266438fc4f3f70fd282d3b0f67a3334",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.",
                "category": "company",
                "datetime": 1788470270,
                "headline": "Protolabs CEO sees big impact from US reshoring despite potential tariffs"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141400340,
                "url": "https://finnhub.io/api/news?id=d605837c09a466bf298019b4b1f79af8743705ece69897637d710b520f1b2b7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.",
                "category": "company",
                "datetime": 1788449092,
                "headline": "Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?"
              },
              {
                "id": 141400349,
                "url": "https://finnhub.io/api/news?id=d83525d9568d496cf432be05e0bc3130c4d26f569d0d1889194d2d2637e7a386",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.",
                "category": "company",
                "datetime": 1788447720,
                "headline": "ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?"
              },
              {
                "id": 141400348,
                "url": "https://finnhub.io/api/news?id=c713b71330fa32d06e3d764e47076891791db9e7f2eaf72967dd5569d778a719",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of several targeted therapies in recent years.",
                "category": "company",
                "datetime": 1788446465,
                "headline": "AbbVie could take BiTE of Tecvayli market share on Phase III MM win"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141381192,
                "url": "https://finnhub.io/api/news?id=25aeb44b56fdd20c2fbb9f307c3b06084c52f1427f4e9e95d1593db372bd106b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State",
                "category": "company",
                "datetime": 1788381834,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 141381193,
                "url": "https://finnhub.io/api/news?id=2b3549b7f8cb8125eb4f126f266bc4f7b1ff45999bedafe3fbd3f7d0c3d75f3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.",
                "category": "company",
                "datetime": 1788381469,
                "headline": "ISRG Stock: The Best House On The Block Costs The Most"
              },
              {
                "id": 141380628,
                "url": "https://finnhub.io/api/news?id=3d5999f99d3d70489597e0eeb51dc1519b38da9070a57d818d88790b55b24950",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Get insights into the dow jones index performance on Wednesday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1788376206,
                "headline": "Discover which dow jones stocks are making waves on Wednesday."
              },
              {
                "id": 141379530,
                "url": "https://finnhub.io/api/news?id=de9681a0ee09a77cf542eab958e12b5cad3038528e2ac5c18cac277bcda9770e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.",
                "category": "company",
                "datetime": 1788375156,
                "headline": "The Wide Divide Priced Into Boston Scientific Stock"
              },
              {
                "id": 141379525,
                "url": "https://finnhub.io/api/news?id=9eb7667fa536ec140822cccdcadd8ff5f2b881704d803756633f08bdbceba0bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th",
                "category": "company",
                "datetime": 1788374302,
                "headline": "Sector Update: Healthcare Stocks Advance Wednesday Afternoon"
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379526,
                "url": "https://finnhub.io/api/news?id=7609742774f5e8bed439f102b1052b17d41d6485061ad4dde22033c610e2e7ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The new objective implies roughly 16% upside and reflects stronger expectations for J&J's pharmaceutical pipeline.",
                "category": "company",
                "datetime": 1788370973,
                "headline": "J&J Jumps as UBS Lifts Its Target to $320"
              },
              {
                "id": 141379527,
                "url": "https://finnhub.io/api/news?id=2c4bf2f82b092b986fc284628cbe56ac62dcb5dd94015d2f4f05a066415ae9af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline",
                "category": "company",
                "datetime": 1788367729,
                "headline": "Johnson & Johnson's Drug Pipeline Supports Growth Outlook, UBS Securities Says"
              },
              {
                "id": 141378556,
                "url": "https://finnhub.io/api/news?id=430d022c59f8a55c66215f07ef9914e0acef1865ae2c24299355d9e8eb701ee6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1788367206,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 141379528,
                "url": "https://finnhub.io/api/news?id=fde9926d0e5f8b6eceb1055b661a894fbdbbfb2068c3f43055e6c03927459747",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Dow was on the rise early in Wednesday's trading session, and the gains were being felt broadly across the blue-chip index. The Dow Jones Industrial Average was up 0.6%, or 326 points, while the S&P 500 and Nasdaq Composite ticked higher, rising 0.",
                "category": "company",
                "datetime": 1788362023,
                "headline": "Dow Adds 300 Points, With Most Stocks Taking Part in the Rally"
              },
              {
                "id": 141379514,
                "url": "https://finnhub.io/api/news?id=be26bbec50ca5a5b43eebb50858927fd3ecc60fec2a00862e209b8f346cbf49c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.",
                "category": "company",
                "datetime": 1788361800,
                "headline": "AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks"
              },
              {
                "id": 141376374,
                "url": "https://finnhub.io/api/news?id=2a8979039ebaaf7b6d5392f1bc96fe416ee0d3b60acb0bf2b886e385d84c6bdf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.",
                "category": "company",
                "datetime": 1788360420,
                "headline": "J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?"
              },
              {
                "id": 141379150,
                "url": "https://finnhub.io/api/news?id=fac6b53077cb17d7af20e819aacca07cf62593653b986be157b110f4bed8e7fd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1788356125,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141376375,
                "url": "https://finnhub.io/api/news?id=af029eeaaa215e97df83177538b4c28f2a2360e5e2dc556ed2bada0cecef8321",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technologyWALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor. Sarich",
                "category": "company",
                "datetime": 1788352200,
                "headline": "OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor"
              },
              {
                "id": 141379529,
                "url": "https://finnhub.io/api/news?id=220c46927503229477ccba4ebb69b058f7672d14a0bdb6b4f3691fbb02891a82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The orthopedics specialist aims to launch a knee robot in late 2028, followed by a shoulder robot in 2029.",
                "category": "company",
                "datetime": 1788346800,
                "headline": "Enovis inks eCential takeover to develop surgical ortho robots"
              },
              {
                "id": 141377766,
                "url": "https://finnhub.io/api/news?id=0165e1463d1709098ac520566acfac2d6c1333b6e396b20b2e4873e9e734132d",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "UBS  analyst Michael Yee   maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $280 to $320.",
                "category": "company",
                "datetime": 1788342090,
                "headline": "UBS Maintains Buy on Johnson & Johnson, Raises Price Target to $320"
              },
              {
                "id": 141375563,
                "url": "https://finnhub.io/api/news?id=7ab5bcd12588ce30f4b5b5a311969bf31606f4bc2cce08218a7a22084c60a831",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson's valuation is above historical averages, already pricing in competent execution. Find out why JNJ stock is a hold.",
                "category": "company",
                "datetime": 1788334184,
                "headline": "Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half"
              },
              {
                "id": 141373023,
                "url": "https://finnhub.io/api/news?id=e3266eba8d7c7f32c4ee173ae3bfd8a04ad772c1b53d5cd7267bcbf9be985087",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) was found liable by a Louisiana jury in a high-profile talc-related mesothelioma case, adding a fresh verdict to its ongoing talc litigation. The jury decision centers on alleged asbestos exposure from Johnson & Johnson talc products and raises questions about potential future legal costs for the company. This verdict contributes to the broader legal overhang that investors weigh alongside Johnson & Johnson's core healthcare operations and balance sheet...",
                "category": "company",
                "datetime": 1788318651,
                "headline": "Does Johnson & Johnson (JNJ) Talc Verdict Add To Its Legal Risk?"
              },
              {
                "id": 141373021,
                "url": "https://finnhub.io/api/news?id=3ce8b5938764a357861e6e95bde47d6bc604547fcc33b8ddc652c6a7c1def557",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.",
                "category": "company",
                "datetime": 1788302702,
                "headline": "Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts"
              },
              {
                "id": 141373022,
                "url": "https://finnhub.io/api/news?id=217d802aef641ea04580e4d6fe41d7bbda0a247e7cadabff6939e7fd7277755c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replacing nearly $47,000 a year in retirement income without touching principal sounds like a math problem, but the real trap is choosing the wrong yield tier and watching either your paycheck or your nest egg quietly shrink.",
                "category": "company",
                "datetime": 1788298944,
                "headline": "Three Dividend Kings That Pay a 75-Year-Old $3,900 a Month: KO, JNJ, and PEP"
              },
              {
                "id": 141372509,
                "url": "https://finnhub.io/api/news?id=fe39252280e118ff2fa8880a440babc7b5b782509ec2959aebf8fd673a741e95",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "GMO’s 13F portfolio jumps to ~$44B. See top holdings, key buys/sells, and rebalancing across tech, healthcare & financials—read the update now.",
                "category": "company",
                "datetime": 1788296759,
                "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2026 Update"
              },
              {
                "id": 141378635,
                "url": "https://finnhub.io/api/news?id=e4e18d878304530ff690fd40e3e9194a40a530d4efe228b4c517b51541d5d5b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108353953-1787671978491-Traders-20260825-AS-PRESS-7.jpg?v=1787672206&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Stocks rose on Wednesday as U.S. Treasury yields took a breather from the recent run-up that sent them to multiyear highs.",
                "category": "company",
                "datetime": 1788285670,
                "headline": "Stocks rise for first time in four sessions as Treasury yields take breather: Live updates"
              },
              {
                "id": 141368965,
                "url": "https://finnhub.io/api/news?id=c80d53f7cac54342cabbb62192f561e4ee503d10c3a9000331444aeb6824eebf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1788280806,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 141371042,
                "url": "https://finnhub.io/api/news?id=c3d97f2474ba1492f45d4aefcbd682b0faccc912990f1b6b655e1715fbc06cb6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2282553745/image_2282553745.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.",
                "category": "company",
                "datetime": 1788280574,
                "headline": "Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside"
              },
              {
                "id": 141360868,
                "url": "https://finnhub.io/api/news?id=2dc6ebba6b34786ca4700a223257fa9da317abedd416a51346a09587ca2924c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.",
                "category": "company",
                "datetime": 1788271516,
                "headline": "Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story"
              },
              {
                "id": 141360878,
                "url": "https://finnhub.io/api/news?id=6285ab8a2996ebc62e91314f0112811611b3c12169f682a695bafe24f1e0f03c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.",
                "category": "company",
                "datetime": 1788257330,
                "headline": "The hidden scale-out problem behind CAR-T’s growth"
              },
              {
                "id": 141360880,
                "url": "https://finnhub.io/api/news?id=9f26bd8922432f5a0314cbcbab75d980716eaa1f1418c04dae1e6c70cefd2ab9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.",
                "category": "company",
                "datetime": 1788227277,
                "headline": "The Peer-Group Mispricing Sitting On BSX Stock"
              },
              {
                "id": 141360828,
                "url": "https://finnhub.io/api/news?id=28c2d62223d73d68b59ad1d81c7fd873fd5841d47ee6c8b1683b66f5d67e1ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788217694,
                "headline": "Chris Benecchi Named Inventiva’s New Chief Operating Officer"
              },
              {
                "id": 141360869,
                "url": "https://finnhub.io/api/news?id=0bcda82b27d3a180b2b577e820b23f9d92e878feec964009192b7f60e44dc52e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., August 31, 2026--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executi",
                "category": "company",
                "datetime": 1788214080,
                "headline": "Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results"
              },
              {
                "id": 141360882,
                "url": "https://finnhub.io/api/news?id=c83871103d89b96e4879c4c93ac0104c1a42a373529f108c9d1ae4b722ee9f5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JEPI's monthly payouts have quietly shrunk all year while the broader market surged past it, and the one event that could reverse both trends is now closer than most investors expect.",
                "category": "company",
                "datetime": 1788208414,
                "headline": "JEPI’s Monthly Payouts Shrunk as the Bull Market Raged. Here’s When That Changes"
              },
              {
                "id": 141360883,
                "url": "https://finnhub.io/api/news?id=13f1d53f984f2a798b1f99ad693f91cc948a8ce1087a978e73f52d0d9f1c3599",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV. The approval marks the company’s second FDA-approved medicine this year, following the M",
                "category": "company",
                "datetime": 1788202929,
                "headline": "Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment"
              },
              {
                "id": 141360820,
                "url": "https://finnhub.io/api/news?id=1df0df20de7aabb85df09fc4c34c5731bfc6fe40781bd266d3afd73797d03fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.",
                "category": "company",
                "datetime": 1788202928,
                "headline": "This Popular Healthcare ETF Is Diluting Your Dividend Income"
              },
              {
                "id": 141360870,
                "url": "https://finnhub.io/api/news?id=3940eba2f9e552a33646a0657cfce9c2e5a582261d24899fe708d82efeab8c82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.",
                "category": "company",
                "datetime": 1788195506,
                "headline": "Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends"
              },
              {
                "id": 141360871,
                "url": "https://finnhub.io/api/news?id=01d50a58902ad14122590b5e4c051c3365746c1cedbbcf46d7f1a717242489d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Three consumer giants have kept raising their dividends through oil shocks, financial crises, and every other economic storm since 1970, and the cash flow numbers behind their streaks reveal why retirees treat them less like investments and more like utilities.",
                "category": "company",
                "datetime": 1788195190,
                "headline": "These 3 Dividend Stocks Have Survived Every Recession Since 1970. Retirees Trust Them for a Reason."
              },
              {
                "id": 141360884,
                "url": "https://finnhub.io/api/news?id=352ccb9dbc196e7fd72c636ec84aecaf01f3e6b3516908358b7cc115d9b040a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.",
                "category": "company",
                "datetime": 1788194220,
                "headline": "From Padcev to PF-08634404: Pfizer's Oncology Growth Push"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141360885,
                "url": "https://finnhub.io/api/news?id=7a515e1f7c83165345ae5a18e438b61fe8540e1077ab0afb529f6f413d6fa8d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stellantis Appoints Stephanie Hartgrove Chief Communications Officer; Names Clara Ingen-Housz to Lead Public Policy & Regulatory Strategy, International Trade AMSTERDAM, August 31, 2026 – Stellantis today announced two senior leadership appointments, effective September 1, strengthening the Company’s communications and public policy leadership. Stephanie Hartgrove has been appointed Chief Communications Officer, reporting to CEO Antonio Filosa, and joins the Stellantis Leadership Team. Hartgrove",
                "category": "company",
                "datetime": 1788185040,
                "headline": "Stellantis Appoints Stephanie Hartgrove Chief Communications Officer; Names Clara Ingen-Housz to Lead  Public Policy & Regulatory Strategy, International Trade"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141360872,
                "url": "https://finnhub.io/api/news?id=cc18a180aac30171ad3fdbaf6532b4cad49cfb62c06beb0ffdbd390500af55ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One of J&J's investments stands head-and-shoulders above the rest.",
                "category": "company",
                "datetime": 1788170640,
                "headline": "Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch."
              },
              {
                "id": 141360873,
                "url": "https://finnhub.io/api/news?id=6b7828153da95e7d98471f4497d58e848236a54aadd439f193674200df7e7991",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials",
                "category": "company",
                "datetime": 1788170580,
                "headline": "Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel"
              },
              {
                "id": 141360874,
                "url": "https://finnhub.io/api/news?id=2de2acf2fb7e0b10db5534509fd4bf526c1f43ddbb5f0b43dce3a1596a3aa9bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Converting a nest egg into a reliable monthly paycheck sounds straightforward until you realize the yield tier you choose can demand nearly three times as much capital for the same income target. A 79-year-old widow with fixed expenses and no room for error found a middle path most retirees overlook entirely.",
                "category": "company",
                "datetime": 1788100618,
                "headline": "How a 79-Year-Old Widow Built a $6,100 Monthly Paycheck Around O, JNJ, and PFF"
              },
              {
                "id": 141348564,
                "url": "https://finnhub.io/api/news?id=7009d4f82a8712cebfa86427db9a724d72e0b2b5febcd81764d5d26f56545d3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.",
                "category": "company",
                "datetime": 1788028861,
                "headline": "AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141348565,
                "url": "https://finnhub.io/api/news?id=7b2a564c1deb0fb5a2fdcb2096dcb5f49bc8b1ca5d3f8c0d45e55a888c4bf309",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.",
                "category": "company",
                "datetime": 1788027132,
                "headline": "Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?"
              },
              {
                "id": 141348566,
                "url": "https://finnhub.io/api/news?id=15eecdb0bafcccf96f222294269137bb40bb43f8e3c60ac364233300dfeba9ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock has delivered an 81.9% gain over the past three years, yet the valuation picture is split between an intrinsic value estimate that points to upside and market multiples that lean the other way. With recent approvals in key therapies alongside ongoing legal exposure, investors are weighing how much of Johnson & Johnson’s story is already reflected in the current share price. The 81.9% return over three years signals that Johnson & Johnson has rewarded longer term...",
                "category": "company",
                "datetime": 1787994704,
                "headline": "Johnson & Johnson (JNJ) Stock Looks Reasonable On Its 82% Three Year Run"
              },
              {
                "id": 141348567,
                "url": "https://finnhub.io/api/news?id=a379190190bdec036257d2748e072424c5c1b755ec036e7bddcd9936dbdcf104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]",
                "category": "company",
                "datetime": 1787974085,
                "headline": "Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb"
              },
              {
                "id": 141341224,
                "url": "https://finnhub.io/api/news?id=a70f356816315e6c1cffbf3ddb6582552dedd39464f32f29f67f627611d5c738",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend activity recap for Champions, Contenders & Challengers: dividend changes plus upcoming ex-dividend and pay dates. See more here.",
                "category": "company",
                "datetime": 1787954658,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 30"
              },
              {
                "id": 141340370,
                "url": "https://finnhub.io/api/news?id=e708a3e3caeb62d314bc7aff88a96587fd102498e635e11de24aa36ba67757bd",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis",
                "category": "company",
                "datetime": 1787936718,
                "headline": "FDA Approves Stelara for Pediatric Ulcerative Colitis"
              },
              {
                "id": 141338793,
                "url": "https://finnhub.io/api/news?id=bd81a66323ddaec8a6c063ad55e9bab105eb706d36589a0de58b89f58003aded",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report",
                "category": "company",
                "datetime": 1787921002,
                "headline": "World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency"
              },
              {
                "id": 141336283,
                "url": "https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.",
                "category": "company",
                "datetime": 1787894920,
                "headline": "Best Dividend Aristocrats For September 2026"
              },
              {
                "id": 141332096,
                "url": "https://finnhub.io/api/news?id=f91bace257ba0af744e76346de1ee986e0b1ace6e3fd1e564f4da44e81506cdf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1787857806,
                "headline": "Thursday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141331062,
                "url": "https://finnhub.io/api/news?id=5c23c716656d25f98d61da7895898b299ef98b2bd2a7cea04355a7c099030532",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1787848807,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 141329551,
                "url": "https://finnhub.io/api/news?id=320a5de29203b8e44f2edf5548e3915f957e76feed78625c85f5fe1da7b57b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217679967/image_2217679967.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.",
                "category": "company",
                "datetime": 1787818087,
                "headline": "GSK: Still One Of My Top Healthcare Picks"
              },
              {
                "id": 141324625,
                "url": "https://finnhub.io/api/news?id=45b7ccfee9169d8cf3dc418bd809f9b83e3e927cd7530f4e98fda7ca7f6a2c9d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787771406,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 141325689,
                "url": "https://finnhub.io/api/news?id=4c11f9c85f6f5bafd7b1a79ae0b1c9c4a4769f2eeb503138a8fb922a2bc6b595",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-heart-pump-controller-purge-cassette-issue-abiomed",
                "category": "company",
                "datetime": 1787752714,
                "headline": "FDA Issues Early Alert On Abiomed Heart Pump Controller Purge Cassette Issue"
              },
              {
                "id": 141317034,
                "url": "https://finnhub.io/api/news?id=a8858e98310f85462059e252bd76fc3444519de43c88f68833ab57142ce4739b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787676006,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 141318610,
                "url": "https://finnhub.io/api/news?id=9d4b621dd731c3bfdad3a47ce565844d36b00e614299f9ed8ee00b9c70737bcd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.",
                "category": "company",
                "datetime": 1787646173,
                "headline": "Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment"
              },
              {
                "id": 141318611,
                "url": "https://finnhub.io/api/news?id=4ad21d2fea599cdc0d61b706eeab0eaff4b8a34cb50735c66e63a6b821fe3627",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell functionWarm autoimmune hemolytic anemia is a rare, life-threatening",
                "category": "company",
                "datetime": 1787628371,
                "headline": "Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study"
              },
              {
                "id": 141308324,
                "url": "https://finnhub.io/api/news?id=d230e0ece83f4cba236cd869d85db24371c89847d296e0eca3524ccfa078799b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419068069/image_1419068069.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.",
                "category": "company",
                "datetime": 1787561537,
                "headline": "Sanofi: Trump's Vaccine Policy Won't Break The Story"
              },
              {
                "id": 141307500,
                "url": "https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.",
                "category": "company",
                "datetime": 1787547151,
                "headline": "Best Dividend Kings: August 2026"
              },
              {
                "id": 141302662,
                "url": "https://finnhub.io/api/news?id=db2fb799a2d2b70f0dc9a338e3091164c1e667df826fe8a27b5a9e784c37657b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Reaching $6,600 a month in dividend income sounds like a single-number problem, but the capital you actually need swings by more than a million dollars depending on which yield tier you choose and what you give up to get there.",
                "category": "company",
                "datetime": 1787501181,
                "headline": "How to Build $6,600 a Month in Dividend Income From Three Income Buckets"
              },
              {
                "id": 141302658,
                "url": "https://finnhub.io/api/news?id=21d4ca7e74876b659e37383bc7de23d9ba6e82ab875bf3e225232bd910740850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Collecting over $141,000 a year in dividends without selling a single share sounds like a fantasy until you realize the yield you chase determines whether your income grows, stagnates, or quietly cannibalizes itself.",
                "category": "company",
                "datetime": 1787497062,
                "headline": "How to Build $11,800 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 141302659,
                "url": "https://finnhub.io/api/news?id=388469ce8547a5d9a54c7c59bb87e7ceb8561ae8c9c41a8061496fe22685a3cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI®▼ (teclistamab) plus daratumumab for adults with relapsed or refractory multiple myeloma. The decision allows use of the combination as early as second line for patients whose disease has returned or is not responding to prior treatment. The approval is based on Phase 3 data that showed material improvements in patient outcomes versus existing standards of care. This adds another immunotherapy option to Johnson...",
                "category": "company",
                "datetime": 1787494085,
                "headline": "Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma"
              },
              {
                "id": 141302655,
                "url": "https://finnhub.io/api/news?id=03c4af49faa3248a17236f16e54e2ad52d8c77e6aaba2aa9c9e40e4f0b5480d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $19,000 a month from dividends alone sounds like a single problem with one answer, but the yield you chase changes the required nest egg by millions and introduces a completely different set of risks, tax consequences, and long-term tradeoffs.",
                "category": "company",
                "datetime": 1787489589,
                "headline": "The Portfolio Blueprint for Building $19,000 a Month in Dividend Income"
              },
              {
                "id": 141298697,
                "url": "https://finnhub.io/api/news?id=2d5710b92f04902e09f6d2f69fcfa2272cadf3005050fd3d2e8b7aefa776a146",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2290281189/image_2290281189.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) keeps a Buy rating as Q2 2026 sales jump and guidance rises.",
                "category": "company",
                "datetime": 1787437480,
                "headline": "Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push"
              },
              {
                "id": 141302656,
                "url": "https://finnhub.io/api/news?id=eee277137691b8bb1f60da98e4923a7ce57c368a09a3cf7685292136d698180a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Starting yield and dividend growth pull $465,000 in two very different directions over a decade, and choosing the wrong one at 53 could cost you far more than the yield gap suggests.",
                "category": "company",
                "datetime": 1787417991,
                "headline": "How a 53-Year-Old Can Turn $465,000 Into a Monthly Paycheck Machine by 63"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141272166,
                "url": "https://finnhub.io/api/news?id=2a96d4aa691194c3fc85b2b1ae496aa054a0278a839aae1dbc4db975bd1f5df7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Friday.",
                "category": "company",
                "datetime": 1787339405,
                "headline": "Discover which dow jones stocks are making waves on Friday."
              },
              {
                "id": 141278131,
                "url": "https://finnhub.io/api/news?id=89e11e354106d0898435d7a254123a430d13cfd8b0f361ffc7ad70f19589620f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.",
                "category": "company",
                "datetime": 1787338881,
                "headline": "Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening"
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141278122,
                "url": "https://finnhub.io/api/news?id=0977c52a95d29262be27b66940bfe9ff452324b5c75e183fd25e8696ac568783",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S",
                "category": "company",
                "datetime": 1787337803,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 141273578,
                "url": "https://finnhub.io/api/news?id=39359255fee6dd1beadb269dd99f2e2f1d0813d68dd4371fa931522e517ddb8d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Get this week’s Dividend Champions, Contenders & Challengers update: dividend changes, upcoming ex-dividend dates, and pay dates. Read the full list here.",
                "category": "company",
                "datetime": 1787334897,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 23"
              },
              {
                "id": 141278123,
                "url": "https://finnhub.io/api/news?id=9cae0317b65b6eba8d87665a1ecddead57b0139873dabf525dfd582092c9d215",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.",
                "category": "company",
                "datetime": 1787332980,
                "headline": "HALO Stock Rises 36% in a Month: Here's What You Should Know"
              },
              {
                "id": 141278125,
                "url": "https://finnhub.io/api/news?id=c4219d4c8cc06018c3099f6575c54f4f5c3fca8777f4943262f105bf447c2dec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update"
              },
              {
                "id": 141270977,
                "url": "https://finnhub.io/api/news?id=8f9d28002ee9400803c1bc65f23e8d2596ad9b71d181614b5198d194aed28983",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787330405,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 141278133,
                "url": "https://finnhub.io/api/news?id=46096836229cd109886a31607450140798e778ceba0267ef93ba2d063409e8c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.",
                "category": "company",
                "datetime": 1787324760,
                "headline": "Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE?"
              },
              {
                "id": 141278126,
                "url": "https://finnhub.io/api/news?id=ebe5e461e4f5914b214b179ea12aa2bb4137857c500ea7d6ac2d3397935dd4c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges.",
                "category": "company",
                "datetime": 1787318820,
                "headline": "Merck vs. J&J: Which Healthcare Giant Should Investors Choose?"
              },
              {
                "id": 141278127,
                "url": "https://finnhub.io/api/news?id=5dadccaac1a006ef5bb2d2699d5418ad82ec3a26a87def6d58ae1eaa5fe4e738",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens1This immunotherapy doublet regimen demonstrated durable disease control as early as second line, with more than 90% of patients who were progression-free at six months remaining progression-free at three years1 BEERSE, BELGIUM, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) h",
                "category": "company",
                "datetime": 1787308800,
                "headline": "European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care"
              },
              {
                "id": 141278134,
                "url": "https://finnhub.io/api/news?id=539c80438bdc4e697ed89aa10e944d59a448c1714225af37503e9183ae75da4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $267.37, marking a -2.21% move from the previous day.",
                "category": "company",
                "datetime": 1787265903,
                "headline": "Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 141278135,
                "url": "https://finnhub.io/api/news?id=159fe45d25dd0dd568eac487d39e684601b9b781ccd3b07bd95702c0db180199",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is back in focus after its stock moved higher following a 6.6% rise in second quarter sales and an improved outlook for 2026. See our latest analysis for Johnson & Johnson. The recent second quarter update and regulatory news around Johnson & Johnson's MONARCH QUEST 3 system have come alongside strong momentum, with a 30 day share price return of 9.88% and an 81.38% total shareholder return over three years. This suggests investors have increasingly rewarded its...",
                "category": "company",
                "datetime": 1787260406,
                "headline": "Johnson & Johnson (JNJ) On Strong Results And 2026 Outlook Why Valuation Is Back In Focus"
              },
              {
                "id": 141278041,
                "url": "https://finnhub.io/api/news?id=b6b8b6bb83ce7842471b2d3ff17fd226a74f65641d1cab1c940ba182d5fc7a99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.",
                "category": "company",
                "datetime": 1787250436,
                "headline": "Merck Stock Ran On A Checklist Published In Advance"
              },
              {
                "id": 141278042,
                "url": "https://finnhub.io/api/news?id=a185f67366da2df6e04ff21b866c03090a3bb454dfce33b84acf2978013b48e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.",
                "category": "company",
                "datetime": 1787248494,
                "headline": "Pfizer Stock Is A Race Between New Drugs And Old Patents"
              },
              {
                "id": 141278128,
                "url": "https://finnhub.io/api/news?id=6ae953c0c2a0889b6642fd3164e527ee58f54d9cc09703b5237c69b976de98ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.",
                "category": "company",
                "datetime": 1787242320,
                "headline": "Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future"
              },
              {
                "id": 141278139,
                "url": "https://finnhub.io/api/news?id=fcd332a3e0e30fe8a0f7d63cb0a926be225e4bb853171cc00071bc6cf71d34d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.",
                "category": "company",
                "datetime": 1787240431,
                "headline": "Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO"
              },
              {
                "id": 141262581,
                "url": "https://finnhub.io/api/news?id=f8a4cc739e42f118d751acb01d597927956e108b45fcd4eabc8bb91e6c7d373f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229232770/image_2229232770.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Stryker (SYK) rebounds with 9% organic growth in Q2 as key segments accelerate.",
                "category": "company",
                "datetime": 1787231457,
                "headline": "Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect"
              },
              {
                "id": 141263972,
                "url": "https://finnhub.io/api/news?id=c214f7edde73e38268c28f3292e33e368242c402dff0bce82285ce82ed18e751",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.",
                "category": "company",
                "datetime": 1787223588,
                "headline": "Why Is Merck Stock Still Undervalued After An 80% Surge?"
              },
              {
                "id": 141265019,
                "url": "https://finnhub.io/api/news?id=3efe1267e5f6f11310f69d408807179b90b236964e8bbc86180a9ae298656234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.",
                "category": "company",
                "datetime": 1787173696,
                "headline": "Johnson & Johnson Stock Runs On A Calendar The Market Does Not Set"
              },
              {
                "id": 141278141,
                "url": "https://finnhub.io/api/news?id=f9a21b5be4efd6c3499dc4de20ff1853c616d3d46fa5e2c4daf0a6b0846d3792",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.",
                "category": "company",
                "datetime": 1787172052,
                "headline": "Is AbbVie Stock About To Break Out Again?"
              },
              {
                "id": 141278142,
                "url": "https://finnhub.io/api/news?id=54387e120c80ab99f828bd23591ac62cb7c9dc15e4d34a4198920e21bfd966dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.",
                "category": "company",
                "datetime": 1787168400,
                "headline": "Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?"
              },
              {
                "id": 141278143,
                "url": "https://finnhub.io/api/news?id=1d3df2215833561fd1be2c6edc2abe71630998ac9a6498e48a23e158b2a81595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.",
                "category": "company",
                "datetime": 1787155560,
                "headline": "Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 141261690,
                "url": "https://finnhub.io/api/news?id=7a9607d856e0e82042b208f8482169a113e1eb6033cde411e37384ae17f4bbe1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson secures FDA clearance for MONARCH QUEST 3 software, boosting robotic bronchoscopy accuracy with AI. new 3D imaging tools.",
                "category": "company",
                "datetime": 1787145019,
                "headline": "Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade"
              },
              {
                "id": 141254214,
                "url": "https://finnhub.io/api/news?id=6bbfa9f61ccce2d3cc984bb6f300d2f9f1f2a250cc4104106d379b62a5afa61c",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "On August 18, it was revealed in an SEC filing that Jennifer Taubert, EVP at Johnson & Johnson (NYSE:JNJ) executed a significant exercise of company stock options.\nWhat Happened: Taubert, EVP at Johnson &",
                "category": "company",
                "datetime": 1787137275,
                "headline": "EVP At Johnson & Johnson Exercises Options Worth $2.38M"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141254559,
                "url": "https://finnhub.io/api/news?id=bd02e536795f125fafff8ee1e984a424fa04f12051c32b8b212f5a03bae43852",
                "image": "https://image.cnbcfm.com/api/v1/image/108309663-1779278269382-gettyimages-2263306993-TARGET_EARNS.jpeg?v=1787094405&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "The S&P 500 fell for a third session as elevated bond yields and oil kept stocks under pressure Tuesday. Tune in to CNBC Wednesday for BlackRock's Rick Rieder.",
                "category": "company",
                "datetime": 1787080023,
                "headline": "Wednesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 141246754,
                "url": "https://finnhub.io/api/news?id=c403cfdc8e76b95c2c482fae3fa9b3d407ffa166cf0ae935a0f4797898d64f03",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1787071206,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141243872,
                "url": "https://finnhub.io/api/news?id=61ee943e8a5ea86e0618df87089dc0f85d75957dfa74acbe00fae233eab250ca",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367003806/image_1367003806.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins. Click here to read why SYK stock is a Hold.",
                "category": "company",
                "datetime": 1787015863,
                "headline": "Stryker Corporation: Hold For Quality, Wait For The Dip"
              },
              {
                "id": 141240002,
                "url": "https://finnhub.io/api/news?id=ec0668889a4c1c71892f8037054930e2b4ad337fa2c786bae0c8ac483da2e41c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1786993806,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 141238736,
                "url": "https://finnhub.io/api/news?id=b91ca1b80516fc75a10e9df868b364cf20cf41b442449092f5176ac5b0392a13",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1786984806,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 141237243,
                "url": "https://finnhub.io/api/news?id=7a80afc1beebf28007235ca103d8f206f6e4ab8468e2ba1548038609bd9fe248",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Johnson & Johnson passes ChartMill's Best Dividend Stocks screen with a high dividend rating, robust profitability, and solid health. A reliable income pick.",
                "category": "company",
                "datetime": 1786962687,
                "headline": "Johnson & Johnson (NYSE:JNJ): A Dividend Quality Standout"
              },
              {
                "id": 141225892,
                "url": "https://finnhub.io/api/news?id=39c878c307b3cf307c98d1ab7e82660110ac435ef76ffc0d9ce4242fe02540ce",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1786802320,
                "headline": "Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now"
              },
              {
                "id": 141224230,
                "url": "https://finnhub.io/api/news?id=378bd32677ead84815eb5c03e6e3830b56b7b1e398114ef6ed1b456b3a5bcb95",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503342678/image_1503342678.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "A SWAN income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning. Read how to build one here.",
                "category": "company",
                "datetime": 1786781400,
                "headline": "How To Invest $100,000 In A Retiree's SWAN Income Portfolio"
              },
              {
                "id": 141217398,
                "url": "https://finnhub.io/api/news?id=9aa0c7405fb35fba6c170c4b0e6fb0522d03435cb57c024ebca3a1d82648d3f9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1786725606,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141216725,
                "url": "https://finnhub.io/api/news?id=75b3ea82141ce5c2d9b288a912788b857b5a70b3f29d76f59065d6a21564acbb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1282122168/image_1282122168.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why it’s a Buy—new launches, insider buying, cost savings.",
                "category": "company",
                "datetime": 1786705872,
                "headline": "Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead"
              },
              {
                "id": 141212141,
                "url": "https://finnhub.io/api/news?id=b37de892ed668dadc063cca94c87fdf98a4674d68db4572b055b93442e76bb04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]",
                "category": "company",
                "datetime": 1786662446,
                "headline": "Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?"
              },
              {
                "id": 141210844,
                "url": "https://finnhub.io/api/news?id=2bf736f8c82a4e2be8402c591dd67c6328e0044a4c9301341ce2ff92fa7cc5f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.",
                "category": "company",
                "datetime": 1786656117,
                "headline": "How Much More Can Boston Scientific Stock Move After Losing Half Its Value?"
              },
              {
                "id": 141210845,
                "url": "https://finnhub.io/api/news?id=497ad8db27d537e7401288c2c7927079eb372edb1d570a09065e25b7e4c9d1b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Rolling $880,000 into a self-directed IRA sounds like a clean break from the 9-to-5, but generating $5,200 a month from that balance forces a choice between safety and survival that most retirement calculators never show you.",
                "category": "company",
                "datetime": 1786654981,
                "headline": "How a 64-Year-Old Turned an $880,000 401(k) Rollover Into a $5,200 Monthly Paycheck Without Buying an Annuity"
              },
              {
                "id": 141209294,
                "url": "https://finnhub.io/api/news?id=ba7f0f61c40ef0086168e3480bf5c9fdcd372d2ed6ea42a5732ae892200ade92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharmaceutical giant just increased its dividend by 3.1%, now paying $5.36 a share annually.",
                "category": "company",
                "datetime": 1786648320,
                "headline": "Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually."
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141205477,
                "url": "https://finnhub.io/api/news?id=41b3346ec67ad1f4ad86b0dc449930056d36b39e7e47683726bc6e3893cf0f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concu",
                "category": "company",
                "datetime": 1786622400,
                "headline": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results"
              },
              {
                "id": 141206335,
                "url": "https://finnhub.io/api/news?id=d62976004d42faff784e96ff18709f7d421ff45857c8e8cbc331ca79db7aab81",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/Doctor-Hand-Point-Patient-Lung-X-ray-Fil.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.",
                "category": "company",
                "datetime": 1786620105,
                "headline": "Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape"
              },
              {
                "id": 141200509,
                "url": "https://finnhub.io/api/news?id=e592376329a72805d9a9aeb76b4e614c74226f090c0ad68a111e0bb4d3e4df81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.",
                "category": "company",
                "datetime": 1786570649,
                "headline": "The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income"
              },
              {
                "id": 141200510,
                "url": "https://finnhub.io/api/news?id=3a4f37e9bb9be44c5b31a36dd018aad8cc0bef3e357de5ae535c60b164dcc0c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return declining 16.1%. The recent 7 day...",
                "category": "company",
                "datetime": 1786569196,
                "headline": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141200513,
                "url": "https://finnhub.io/api/news?id=c73a8f0475758d31cd448380b74cbbb1c57e712f593a1a9679b90a05f53a54ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.",
                "category": "company",
                "datetime": 1786559422,
                "headline": "Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield"
              },
              {
                "id": 141200514,
                "url": "https://finnhub.io/api/news?id=26115dcb89643ffe9ddf725edb926159cea0317a8a8a874e34930e18eb09dc90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.",
                "category": "company",
                "datetime": 1786555201,
                "headline": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical"
              },
              {
                "id": 141200500,
                "url": "https://finnhub.io/api/news?id=ff75988727fcba1e5d818840746487c01f069e154db33e9b2aabc87f756101ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Four dividend giants from energy and pharma quietly generate the bulk of HDV's income, but their balance sheets and payout coverage look nothing alike. Before trusting that 3% yield, it pays to know which checks are ironclad and which carry a hidden catch.",
                "category": "company",
                "datetime": 1786551148,
                "headline": "The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is"
              },
              {
                "id": 141200516,
                "url": "https://finnhub.io/api/news?id=16389bf6a4738707ea856c733b9d74175e963f8518fb7792090d6671148e0639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson’s focus on higher growth therapeutic and medtech areas that are important for its long term...",
                "category": "company",
                "datetime": 1786551101,
                "headline": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care"
              },
              {
                "id": 141200517,
                "url": "https://finnhub.io/api/news?id=07b0a0bf7a9dcaaadfb74ca6213177c3075993d2885f8ca39092b204d4e913c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart.",
                "category": "company",
                "datetime": 1786539571,
                "headline": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\""
              },
              {
                "id": 141200518,
                "url": "https://finnhub.io/api/news?id=78cd813b9ec063ef31be0d6d0b44ffefcc96b5fa0be5dba40387d36f5497337d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.",
                "category": "company",
                "datetime": 1786539024,
                "headline": "Why Revolution Medicines May Be Big Pharma’s Next Takeover Target"
              },
              {
                "id": 141200519,
                "url": "https://finnhub.io/api/news?id=24829641f332e3eb02dac53a3ed12233a7723a96315a57d782297c99b7e59aa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Oppenheimer argues Ottava and Hugo pose no near-term threat to da Vinci",
                "category": "company",
                "datetime": 1786537519,
                "headline": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall"
              },
              {
                "id": 141200520,
                "url": "https://finnhub.io/api/news?id=c65b94e0e43f9872242ec47658569bc36e250f115a7c36b06abfd22d6dc9d7be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (“J&J”) and is a member of J&J’s Executive Committee, where he",
                "category": "company",
                "datetime": 1786536000,
                "headline": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors"
              },
              {
                "id": 141193278,
                "url": "https://finnhub.io/api/news?id=357ca417d488522e729cb4788731a4e9c2bf02f33e056d92c95bfe0f40e34f92",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202854526/image_1202854526.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Intuitive Surgical (ISRG) stock analysis: Hold rating with $426.65 price target (+9% upside).",
                "category": "company",
                "datetime": 1786532243,
                "headline": "Intuitive Surgical: Priced For Precision"
              },
              {
                "id": 141189365,
                "url": "https://finnhub.io/api/news?id=3af242c14af2e122129a8e9419b3189b5d2cbedcadc8635aa37d3a59154b3ac7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.",
                "category": "company",
                "datetime": 1786489797,
                "headline": "JNJ Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 141190121,
                "url": "https://finnhub.io/api/news?id=6122dcbbe887770943e505b8e118b1a6814c928f257ef65b6a02dcccc21b63a2",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1786485283,
                "headline": "Tracking AMG's Yacktman Asset Management Portfolio - Q2 2026 Update"
              },
              {
                "id": 141200522,
                "url": "https://finnhub.io/api/news?id=f0d51c7ab430a8d753995618c9da44e3d2e03deb47af505ce082f9d74ce6f8d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "These stocks can help you withstand (almost) any storm.",
                "category": "company",
                "datetime": 1786485000,
                "headline": "The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession"
              },
              {
                "id": 141189366,
                "url": "https://finnhub.io/api/news?id=875b935af433bfa3030edf6eff7cc254c4ffb82289f22197cb75fd2f1a2404bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.",
                "category": "company",
                "datetime": 1786484330,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off"
              },
              {
                "id": 141189535,
                "url": "https://finnhub.io/api/news?id=8b7ddc3ba19accdc7c3f8b168aa7e62c548c4d2b85b10b4bc213275a31351fec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "High-yield ETFs built purely on yield rankings carry a hidden flaw that only shows up when it's too late, and one fund uses a decade-long dividend track record as a filter before yield ever enters the picture.",
                "category": "company",
                "datetime": 1786481297,
                "headline": "This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It’s Up 18.5% in 2026"
              },
              {
                "id": 141200525,
                "url": "https://finnhub.io/api/news?id=9bd6de94561c5f9895f0a16d21318d11b3e108f3082cc2010fca44440741e616",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has surged more than 50% in a year and now sits within striking distance of its 52-week high, but a closer look at the valuation, insider activity, and pipeline pressures raises a pointed question about who actually wins from here.",
                "category": "company",
                "datetime": 1786473051,
                "headline": "Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?"
              },
              {
                "id": 141200526,
                "url": "https://finnhub.io/api/news?id=bb45ea9039c763833121ecfb68e434d16b3cf6fb8431480eca4c3f9568d605b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.",
                "category": "company",
                "datetime": 1786467240,
                "headline": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?"
              },
              {
                "id": 141200527,
                "url": "https://finnhub.io/api/news?id=c26f0c93d5ac13d1ee53f2b75881070c80f4c7f2f90f49190e34322cdd77efa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.",
                "category": "company",
                "datetime": 1786467026,
                "headline": "Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus"
              },
              {
                "id": 141200528,
                "url": "https://finnhub.io/api/news?id=43b7700b45a73638a49c042ec837866828a15b04a4cd6839ebd11f3a98553acd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.",
                "category": "company",
                "datetime": 1786453920,
                "headline": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?"
              },
              {
                "id": 141181749,
                "url": "https://finnhub.io/api/news?id=f314c7059854892624f29f049cf6afa75d82e766cad9d724e33ec098e825fede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Pulling $54,000 a year from a $950,000 rollover IRA sounds like a math problem, but the real trap is hidden in the yield tier you choose and what it quietly does to your principal over time.",
                "category": "company",
                "datetime": 1786417828,
                "headline": "How a 65-Year-Old Turned a $950,000 401(k) Rollover Into a $4,500 Monthly Paycheck Without Buying an Annuity"
              },
              {
                "id": 141180971,
                "url": "https://finnhub.io/api/news?id=e8e6381f9ed73fb35f8db6760f5729e3f0b640f006cf3deacd9def67d779bf36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these...",
                "category": "company",
                "datetime": 1786407647,
                "headline": "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 201,
            "discarded_article_count": 179
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.7,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.6,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.6,
            "vcp_reason": "波幅收縮(11.5%→6.5%)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 6547280,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 6659990,
              "avg_vol_20": 6247400,
              "avg_vol_30": 6547280,
              "range_pct_10": 0.06472692454563815,
              "range_pct_20": 0.09690263199164133,
              "range_pct_30": 0.11499908334901124,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0172147823218192,
              "dist_to_20d_high": 0.05237128342904257,
              "down_shrink_days": 2,
              "breakout_level_20d": 281.070007,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5628473085233047
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 2,
            "details": {
              "atrPct": 1.9858456172012158,
              "turnoverUsdM": 1290.3637863961699,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.JNJ",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 255.7714,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2.5,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 4,
            "take_profit_price": 279.6675,
            "target_multiplier": 1.6,
            "technical_strength": 1.45,
            "take_profit_percent": 5
          },
          "positionPoints": 2,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2589095437959654,
          "stopLossPercent": 3.9716912344024315,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.JNJ",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 5.2893,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.99
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -27.27
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0119
    },
    "kdj": {
      "d": 46.38,
      "j": 4.38,
      "k": 32.38,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 48.14
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 91184983,
      "recentSlope": -562401.7,
      "previousSlope": 1139780
    },
    "rsi": 48.79,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 265.0209,
      "position": "SAR喺價下",
      "distancePct": 0.5,
      "previousTrend": "上升"
    },
    "ma50": 262.4766,
    "macd": {
      "macd": 2.647729026035563,
      "trend": "中性偏多",
      "signal": 3.5075242318431474,
      "histogram": -0.8597952058075844
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 269.4021,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.77,
      "score": 2,
      "avgVolume": 6258166,
      "currentVolume": 4844617
    },
    "derived": {
      "ma20": 269.269,
      "ma50": 262.4766,
      "prevClose": 267.08,
      "avgVolume10": 6423042,
      "avgVolume20": 6258166,
      "changePercent": -0.27,
      "avgVolumeForScore": 6258166
    },
    "ma_cross": {
      "ma20": 269.269,
      "ma50": 262.4766,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 268.9945,
      "prevMa50": 262.229,
      "spreadPct": 2.59,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 259.986,
      "upper": 278.552,
      "position": "中間"
    },
    "rsi_short": 37.47,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.77
    }
  }
}

{
  "close": 266.35,
  "volume": 4844617,
  "changePercent": -0.27
}